Heck Capital Advisors LLC Takes Position in ADMA Biologics, Inc. (NASDAQ:ADMA)

Heck Capital Advisors LLC purchased a new position in ADMA Biologics, Inc. (NASDAQ:ADMA) in the fourth quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund purchased 13,123 shares of the biotechnology company’s stock, valued at approximately $225,000.

Other hedge funds and other institutional investors have also made changes to their positions in the company. State Street Corp grew its holdings in ADMA Biologics by 61.4% during the 3rd quarter. State Street Corp now owns 13,004,993 shares of the biotechnology company’s stock worth $259,970,000 after acquiring an additional 4,945,063 shares in the last quarter. Geode Capital Management LLC grew its stake in ADMA Biologics by 2.6% in the third quarter. Geode Capital Management LLC now owns 5,381,985 shares of the biotechnology company’s stock worth $107,606,000 after purchasing an additional 137,989 shares in the last quarter. Perpetual Ltd bought a new stake in ADMA Biologics in the fourth quarter valued at about $62,300,000. Assenagon Asset Management S.A. raised its stake in ADMA Biologics by 2.7% during the third quarter. Assenagon Asset Management S.A. now owns 3,474,455 shares of the biotechnology company’s stock valued at $69,454,000 after buying an additional 92,281 shares in the last quarter. Finally, Lord Abbett & CO. LLC bought a new position in ADMA Biologics during the 3rd quarter worth approximately $61,858,000. Institutional investors own 75.68% of the company’s stock.

Insider Buying and Selling at ADMA Biologics

In other ADMA Biologics news, CFO Brad L. Tade sold 15,000 shares of the business’s stock in a transaction on Friday, November 22nd. The stock was sold at an average price of $21.15, for a total transaction of $317,250.00. Following the completion of the transaction, the chief financial officer now owns 199,433 shares in the company, valued at approximately $4,218,007.95. The trade was a 7.00 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. 3.70% of the stock is currently owned by company insiders.

ADMA Biologics Stock Up 0.3 %

Shares of ADMA Biologics stock opened at $16.15 on Friday. ADMA Biologics, Inc. has a twelve month low of $5.02 and a twelve month high of $23.64. The stock has a market capitalization of $3.82 billion, a price-to-earnings ratio of 57.68 and a beta of 0.76. The company has a current ratio of 7.09, a quick ratio of 3.26 and a debt-to-equity ratio of 0.48. The business’s 50 day simple moving average is $18.10 and its 200-day simple moving average is $17.58.

ADMA Biologics (NASDAQ:ADMA) last posted its earnings results on Thursday, November 7th. The biotechnology company reported $0.15 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.13 by $0.02. The company had revenue of $119.84 million for the quarter, compared to analysts’ expectations of $107.25 million. ADMA Biologics had a return on equity of 53.20% and a net margin of 17.80%. During the same period last year, the business posted $0.01 earnings per share. Equities research analysts forecast that ADMA Biologics, Inc. will post 0.51 earnings per share for the current year.

Analyst Ratings Changes

A number of brokerages have recently weighed in on ADMA. HC Wainwright boosted their price target on ADMA Biologics from $18.00 to $26.00 and gave the company a “buy” rating in a report on Friday, November 8th. Raymond James increased their target price on shares of ADMA Biologics from $18.00 to $25.00 and gave the stock a “strong-buy” rating in a report on Friday, November 8th.

ADMA Biologics Profile

ADMA Biologics, Inc, a biopharmaceutical company, engages in developing, manufacturing, and marketing specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases in the United States and internationally. The company offers BIVIGAM, an intravenous immune globulin (IVIG) product indicated for the treatment of primary humoral immunodeficiency (PI); ASCENIV, an IVIG product for the treatment of PI; and Nabi-HB for the treatment of acute exposure to blood containing Hepatitis B surface antigen and other listed exposures to Hepatitis B.